CoChat

Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer

Open access
Cappellesso, Federica, Orban, Marie-Pauline, Shirgaonkar, Niranjan, Berardi, Emanuele, Serneels, Jens, Neveu, Marie-Aline, Di Molfetta, Daria, Piccapane, Francesca, Caroppo, Rosa, Debellis, Lucantonio, Ostyn, Tessa, Joudiou, Nicolas, Mignion, Lionel, Richiardone, Elena, Jordan, Bénédicte F., Gallez, Bernard, Corbet, Cyril, Roskams, Tania, DasGupta, Ramanuj, Tejpar, Sabine, Di Matteo, Mario, Taverna, Daniela, Reshkin, Stephan J., Topal, Baki, Virga, Federico, Mazzone, Massimiliano · 2022 · Nature Cancer
Cited by 134

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Solid tumors are generally characterized by an acidic tumor microenvironment (TME) that favors cancer progression, therapy resistance and immune evasion. By single-cell RNA-sequencing analysis in individuals with pancreatic ductal adenocarcinoma (PDAC), we reveal solute carrier family 4 member 4 (SLC4A4) as the most abundant bicarbonate transporter, predominantly expressed by epithelial ductal cells. Functionally, SLC4A4 inhibition in PDAC cancer cells mitigates the acidosis of the TME due to bicarbonate accumulation in the extracellular space and a decrease in lactate production by cancer cells as the result of reduced glycolysis. In PDAC-bearing mice, genetic or pharmacological SLC4A4 targeting improves T cell-mediated immune response and breaches macrophage-mediated immunosuppression, thus inhibiting tumor growth and metastases. In addition,Slc4a4 targeting in combination with immune checkpoint blockade is able to overcome immunotherapy resistance and prolong survival. Overall, our data propose SLC4A4 as a therapeutic target to unleash an antitumor immune response in PDAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-022-00470-2

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 134

Metadata

Authors
Cappellesso, F., Orban, M.-P., Shirgaonkar, N., Berardi, E., Serneels, J., Neveu, M.-A., Di Molfetta, D., Piccapane, F., Caroppo, R., Debellis, L., Ostyn, T., Joudiou, N., Mignion, L., Richiardone, E., Jordan, B. F., Gallez, B., Corbet, C., Roskams, T., DasGupta, R., Tejpar, S., Di Matteo, M., Taverna, D., Reshkin, S. J., Topal, B., Virga, F., & Mazzone, M.
Venue
Nature Cancer
Published
2022-12-15
Volume
3
Issue
12
Pages
1464-1483
ISSN
2662-1347 (ISSN-L)
OpenAlex
W4311748741
Cited by
134
References
17
FWCI
9.34
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. https://app.cochat.ai/papers/10.1038/s43018-022-00470-2
The paper
Cappellesso, F., Orban, M.-P., Shirgaonkar, N., Berardi, E., Serneels, J., Neveu, M.-A., Di Molfetta, D., Piccapane, F., Caroppo, R., Debellis, L., Ostyn, T., Joudiou, N., Mignion, L., Richiardone, E., Jordan, B. F., Gallez, B., Corbet, C., Roskams, T., DasGupta, R., . . . Mazzone, M. (2022). Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nature Cancer. https://doi.org/10.1038/s43018-022-00470-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.